Quinupristin + Dalfopristin is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Patients with serious or life-threatening infections associated with vancomycin-resistant Enterococcus faecium (VREF) bacteremia.
  • Complicated skin and skin structure infections caused by Staphylococcus aureus (MSSA) or Streptococcus pyogenes.

NON-FDA APPROVED USES

  • Endocarditis (generally not recommended due to poorer clearance of bacteremia)

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: January 27, 2016

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Quinupristin + Dalfopristin ID - 540467 A1 - Bartlett,John,M.D. AU - Pham,Paul,Pharm.D. Y1 - 2016/01/27/ BT - Johns Hopkins ABX Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540467/all/Quinupristin_+_Dalfopristin PB - The Johns Hopkins University DB - Pediatrics Central DP - Unbound Medicine ER -